Efficacy and safety of mitiglinide versus nateglinide in newly diagnose patients with type 2 diabetes mellitus: A randomized double blind trial

Diabetes, Obesity and Metabolism

Volumn 14, Issue 2, 2012, Pages 187-189

  Li, L ^a   Yang, M ^a   Li, Z ^a   Yan, X ^b   Guo, H ^c   Pan, H ^d   Liu, H ^e   Liao, Y ^f   Yang, G ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b PEOPLE'S HOSPITAL OF GUANGXI ZHUANG AUTONOMOUS REGION   (China)

^c THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^d FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^e UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^f Chongqing Corps Hospital of Chinese People's Armed Police Forces   (China)

Author keywords

Mitiglinide; Randomized trial; T2DM

Indexed keywords

CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MITIGLINIDE; NATEGLINIDE; TRIACYLGLYCEROL;

ADULT; ARTHRALGIA; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; CONTROLLED STUDY; DIET; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; EXERCISE; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; LETTER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; TRIGLCYERIDE; VOMITING;

EID: 84855358471     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01494.x     Document Type: Letter

References (12)

1. Doyle ME, Egan JM. Pharmacological agents that directly modulate insulin secretion. Pharmacol Rev 2003; 55: 105-131.
2. Shapiro ET, Van Cauter E, Tillil H et al. Glyburide enhances the responsiveness of the beta-cell to glucose but does not correct the abnormal patterns of insulin secretion in noninsulin- dependent diabetes mellitus. J Clin Endocrinol Metab 1989; 69: 571-576.
3. Salas M, Caro JJ. Are hypoglycaemia and other adverse effects similar among sulphonylureas? Adverse Drug React Toxicol Rev 2002; 21: 205-217.
4. Sato Y, Nishikawa M, Shinkai H et al. Possibility of ideal blood glucose control by a new oral hypoglycemic agent, N-[(trans-4-isopropylcyclohexyl)- carbonyl]-D- phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animals. Diabetes Res Clin Pract 1991; 12: 53-59.
5. Phillippe HM, Wargo KA. Mitiglinide: a novel agent for the treatment of type 2 diabetes mellitus. Ann Pharmacother 2010; 44: 1615-1623.
6. Konya H, Miuchi M, Konishi K et al. Pleiotropic effects of mitiglinide in type 2 diabetes mellitus. J Int Med Res 2009; 37: 1904-1912.
7. Bakkali-Nadi A, Malaisse-Lagae F, Malaisse WJ. Ionophoretic activity of meglitinide analogues. Diabetes Res 1994; 27: 61-71.
8. 2B type of ATP-sensitive potassium channel. Br J Pharmacol 2001; 132: 1542-1548.
9. Declaration of Helsinki: Recommendations guiding medical physicians in biomedical research involving human subjects. JAMA 1997; 277: 925-926.
10. Kohei K, Shun-Ichi T, Hideki O et al. Effect of mitiglinide on glycemic control over 52 weeks in Japanese type 2 diabetic patients insufficiently controlled with pioglitazone monotherapy. Endocr J 2009; 56: 739-746.
11. Masanori A, Okada K, Maruyama T et al. Efficacy and safety of mitiglinide in diabetic patients on maintenance hemodialysis. Endocr J 2010; 57: 579-586.
12. Xin G, Zhimin L, Guangwei L et al. Multicentre, double-blind, randomized study of mitiglinide compared with nateglinide in type 2 diabetes mellitus patients in China. J Int Med Res 2009; 37: 812-821.